At a glance
- Ecnoglutide is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 16 publications mentioning it, including 5 randomized controlled trials and 0 animal-only studies.
- ClinicalTrials.gov lists 17 registered studies testing it (7 active).
- FDA’s adverse event system (FAERS) has no reports mentioning it.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Evaluating the therapeutic benefits and safety of ecnoglutide for type 2 diabetes: evidence from a systematic review and meta-analysis.
- Dose-response and time-course effects of ecnoglutide in type 2 diabetes: a systematic review and meta-analysis of efficacy.
- Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
- Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
- Ecnoglutide: First Approvals.
- Effect of a Novel GLP-1 Analogue Ecnoglutide on the Pharmacokinetics of Rosuvastatin and Digoxin in Healthy Participants.
- No dose adjustment required for warfarin or metformin when coadministered with the novel GLP-1 receptor agonist ecnoglutide: an open-label, fixed-sequence, crossover study.
- Comparative Efficacy and Safety of Ecnoglutide in Type 2 Diabetes: A Systematic Review and Meta-Analysis.
- Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial.
- Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 17
- Active
- 7
- With posted results
- 0
Conditions studied
Show 7 more studies
| Study | Status | Phase | Start |
|---|---|---|---|
| A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin | Completed | Phase 1 | July 14, 2023 |
| A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity | Completed | Phase 3 | April 5, 2023 |
| A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM | Completed | Phase 3 | January 10, 2023 |
| A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients | Completed | Phase 3 | December 29, 2022 |
| XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults | Completed | Phase 1 | April 12, 2022 |
| Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity | Completed | Phase 2 | November 30, 2021 |
| To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants | Completed | Phase 1 | March 29, 2020 |
All 17 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
No FAERS reports mention this peptide.
Change history
No changes since monitoring began on October 30, 2026.